MPGES-1 null mice are resistant to bleomycin-induced skin fibrosis

Arthritis Research and Therapy

Volumn 13, Issue 1, 2011, Pages

  McCann, Matthew R ^a   Monemdjou, Roxana ^b   Ghassemi Kakroodi, Parisa ^a   Fahmi, Hassan ^a   Perez, Gemma ^b   Liu, Shangxi ^a   Shi wen, Xu ^c   Parapuram, Sunil K ^a   Kojima, Fumiaki ^d   Denton, Christopher P ^c   Abraham, David J ^c   Martel Pelletier, Johanne ^b   Crofford, Leslie J ^d   Leask, Andrew ^a   Kapoor, Mohit ^b  

^a WESTERN UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN; HYDROXYPROLINE; MICROSOMAL PROSTAGLANDIN E2 SYNTHASE 1; PROSTAGLANDIN E SYNTHASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; ISOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROGENESIS; INJECTION SITE; MALE; MYOFIBROBLAST; NONHUMAN; NULL ALLELE; PROTEIN EXPRESSION; SCLERODERMA; SKIN FIBROBLAST; SKIN FIBROSIS; SKIN INFLAMMATION; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; FIBROBLAST; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, KNOCKOUT; SCLERODERMA, SYSTEMIC;

EID: 78951474761     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3226     Document Type: Article

References (57)

1. Leask A, Denton CP, Abraham DJ. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 2004, 122:1-6. 10.1046/j.0022-202X.2003.22133.x, 14962082.
2. Kapoor M, Appleton I. Wound healing: abnormalities and future therapeutic targets. Current Anaesthesia & Critical Care 2005, 16:88-93.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567. 10.1172/JCI31139, 1804347, 17332883.
4. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977, 20:975-984. 10.1002/art.1780200410, 861067.
5. Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988, 18:9-17. 10.1111/j.1365-2362.1988.tb01158.x, 3130266.
6. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999, 96:7220-7225. 10.1073/pnas.96.13.7220, 22058, 10377395.
7. Tanikawa N, Ohmiya Y, Ohkubo H, Hashimoto K, Kangawa K, Kojima M, Ito S, Watanabe K. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun 2002, 291:884-889. 10.1006/bbrc.2002.6531, 11866447.
8. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000, 275:32775-32782. 10.1074/jbc.M003504200, 10922363.
9. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T, Ohmiya Y, Watanabe K, Kudo I. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003, 278:37937-37947. 10.1074/jbc.M305108200, 12835322.
10. Kojima F, Naraba H, Sasaki Y, Okamoto R, Koshino T, Kawai S. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J Rheumatol 2002, 29:1836-1842.
11. Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 2001, 167:469-474.
12. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, Yasui H, Azuma Y, Hirasawa N, Ohuchi K, Kawaguchi H, Ishikawa Y, Ishii T, Uematsu S, Akira S, Murakami M, Kudo I. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem 2004, 279:33684-33695. 10.1074/jbc.M400199200, 15140897.
13. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003, 100:9044-9049. 10.1073/pnas.1332766100, 166435, 12835414.
14. Saha S, Engstrom L, Mackerlova L, Jakobsson PJ, Blomqvist A. Impaired febrile responses to immune challenge in mice deficient in microsomal prostaglandin E synthase-1. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1100-1107.
15. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003, 278:19396-19405. 10.1074/jbc.M213290200, 12626523.
16. Kojima F, Naraba H, Miyamoto S, Beppu M, Aoki H, Kawai S. Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther 2004, 6:R355-365. 10.1186/ar1195, 464891, 15225371.
17. Kojima F, Naraba H, Sasaki Y, Beppu M, Aoki H, Kawai S. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 2003, 48:2819-2828. 10.1002/art.11261, 14558087.
18. Kapoor M, Kojima F, Yang L, Crofford LJ. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 2007, 76:103-112. 10.1016/j.plefa.2006.11.006, 1847382, 17239574.
19. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 1966, 19:200-209.
20. Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. Exp Dermatol 2005, 14:81-95. 10.1111/j.0906-6705.2005.00280.x, 15679577.
21. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999, 112:456-462. 10.1046/j.1523-1747.1999.00528.x, 10201529.
22. Kojima F, Kapoor M, Yang L, Fleishaker EL, Ward MR, Monrad SU, Kottangada PC, Pace CQ, Clark JA, Woodward JG, Crofford LJ. Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J Immunol 2008, 180:8361-8368. 2435291, 18523303.
23. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009, 60:2822-2829. 10.1002/art.24761, 19714649.
24. Liu S, Kapoor M, Denton CP, Abraham DJ, Leask A. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 2009, 60:2817-2821. 10.1002/art.24801, 19714619.
25. Kapoor M, Liu S, Huh K, Parapuram S, Kennedy L, Leask A. Connective tissue growth factor promoter activity in normal and wounded skin. Fibrogenesis Tissue Repair 2008, 1:3. 10.1186/1755-1536-1-3, 2584011, 19014648.
26. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996, 29:225-229. 10.1016/0009-9120(96)00003-6, 8740508.
27. Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005, 167:1699-1711. 10.1016/S0002-9440(10)61252-7, 1613194, 16314481.
28. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998, 31(Suppl 1):S360-363. 10.1097/00005344-199800001-00101, 9595482.
29. Zheng B, Zhang Z, Black CM, de Crombrugghe B, Denton CP. Ligand-dependent genetic recombination in fibroblasts: a potentially powerful technique for investigating gene function in fibrosis. Am J Pathol 2002, 160:1609-1617. 10.1016/S0002-9440(10)61108-X, 1850857, 12000713.
30. Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ. Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem 2007, 282:5356-5366. 10.1074/jbc.M610153200, 17186945.
31. Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ. Shunting of prostanoid biosynthesis in microsomal prostaglandin E synthase-1 null embryo fibroblasts: regulatory effects on inducible nitric oxide synthase expression and nitrite synthesis. Faseb J 2006, 20:2387-2389. 10.1096/fj.06-6366fje, 17023389.
32. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4:583-594. 10.1038/nri1412, 2702150, 15286725.
33. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, Riendeau D, Mancini JA. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 2003, 170:4738-4744.
34. Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC, Riendeau D. Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J Biol Chem 2001, 276:4469-4475. 10.1074/jbc.M006865200, 11067848.
35. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783-32792. 10.1074/jbc.M003505200, 10869354.
36. Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992, 19:1202-1206.
37. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005, 64:1233-1235. 10.1136/ard.2004.027094, 1755597, 16014686.
38. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35:67-72. 10.1002/art.1780350111, 1731816.
39. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43:2455-2463. 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K, 11083268.
40. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006, 2:679-685. 10.1038/ncprheum0346, 17133253.
41. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003, 200:500-503. 10.1002/path.1427, 12845617.
42. Leask A. Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis Tissue Repair 2010, 3:8. 10.1186/1755-1536-3-8, 2890590, 20507556.
43. Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009, 21:617-622. 10.1097/BOR.0b013e32832fd69e, 2848972, 19633559.
44. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595. 10.1016/j.it.2005.09.004, 16168711.
45. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000, 275:15220-15225. 10.1074/jbc.275.20.15220, 10809757.
46. Verrecchia F, Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 2004, 16:873-880. 10.1016/j.cellsig.2004.02.007, 15157666.
47. Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, Peschon JJ, Schmidts HL, Brody AR, Friedman M. Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999, 20:825-833.
48. Liu JY, Brass DM, Hoyle GW, Brody AR. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998, 153:1839-1847. 10.1016/S0002-9440(10)65698-2, 1866331, 9846974.
49. Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, Kollias G, Aidinis V. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One 2006, 1:e108. 10.1371/journal.pone.0000108, 1762410, 17205112.
50. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001, 108:241-250. 203022, 11457877.
51. Ricupero DA, Rishikof DC, Kuang PP, Poliks CF, Goldstein RH. Regulation of connective tissue growth factor expression by prostaglandin E(2). Am J Physiol 1999, 277:L1165-1171.
52. Xiao R, Kanekura T, Yoshida N, Higashi Y, Yan KL, Fukushige T, Kanzaki T. 9-Cis-retinoic acid exhibits antifibrotic activity via the induction of cyclooxygenase-2 expression and prostaglandin E2 production in scleroderma fibroblasts. Clin Exp Dermatol 2008, 33:484-490. 10.1111/j.1365-2230.2008.02727.x, 18462443.
53. Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen 2007, 15:122-133. 10.1111/j.1524-475X.2006.00193.x, 17244328.
54. Sokolova E, Hartig R, Reiser G. Downregulation of protease-activated receptor-1 in human lung fibroblasts is specifically mediated by the prostaglandin E receptor EP2 through cAMP elevation and protein kinase A. FEBS J 2008, 275:3669-3679. 10.1111/j.1742-4658.2008.06511.x, 18537828.
55. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995, 95:1861-1868. 10.1172/JCI117866, 295728, 7706493.
56. Stratton R, Shiwen X. Role of prostaglandins in fibroblast activation and fibrosis. J Cell Commun Signal 2010, 4:75-77. 10.1007/s12079-010-0089-8, 2876240, 20531982.
57. Lemaire R, Bayle J, Lafyatis R. Fibrillin in Marfan syndrome and tight skin mice provides new insights into transforming growth factor-beta regulation and systemic sclerosis. Curr Opin Rheumatol 2006, 18:582-587. 10.1097/01.bor.0000245719.64393.57, 17053502.